Boston Scientific Co. (NYSE:BSX) Shares Acquired by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. increased its position in Boston Scientific Co. (NYSE:BSX - Free Report) by 8.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 696,124 shares of the medical equipment provider's stock after acquiring an additional 53,471 shares during the period. Asset Management One Co. Ltd.'s holdings in Boston Scientific were worth $63,090,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BSX. TFC Financial Management Inc. increased its position in Boston Scientific by 308.8% during the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 210 shares during the last quarter. Values First Advisors Inc. purchased a new stake in Boston Scientific in the 3rd quarter worth approximately $28,000. Dunhill Financial LLC raised its stake in Boston Scientific by 86.4% during the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 152 shares during the period. Global Wealth Strategies & Associates lifted its holdings in Boston Scientific by 423.7% during the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock valued at $28,000 after purchasing an additional 250 shares in the last quarter. Finally, West Oak Capital LLC bought a new position in shares of Boston Scientific in the fourth quarter worth approximately $29,000. 89.07% of the stock is owned by institutional investors.

Boston Scientific Trading Down 0.7 %

BSX traded down $0.79 on Tuesday, reaching $105.32. 6,482,220 shares of the company traded hands, compared to its average volume of 6,045,374. The company has a market cap of $155.22 billion, a P/E ratio of 84.26, a price-to-earnings-growth ratio of 2.79 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a one year low of $65.33 and a one year high of $107.17. The firm has a fifty day simple moving average of $96.79 and a two-hundred day simple moving average of $88.61.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. As a group, equities research analysts expect that Boston Scientific Co. will post 2.83 earnings per share for the current year.

Analysts Set New Price Targets

BSX has been the topic of a number of analyst reports. StockNews.com upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a research note on Wednesday, January 29th. Canaccord Genuity Group increased their target price on Boston Scientific from $98.00 to $101.00 and gave the stock a "buy" rating in a research report on Monday, December 9th. Citigroup boosted their price target on Boston Scientific from $107.00 to $122.00 and gave the stock a "buy" rating in a report on Thursday, February 6th. Truist Financial lifted their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Wednesday, December 18th. Finally, Bank of America raised their target price on shares of Boston Scientific from $90.00 to $100.00 and gave the company a "buy" rating in a research note on Tuesday, October 22nd. One equities research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $107.39.

Insider Activity

In related news, Director Edward J. Ludwig sold 4,877 shares of the business's stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the transaction, the director now owns 39,398 shares of the company's stock, valued at $3,610,038.74. The trade was a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction on Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the sale, the executive vice president now directly owns 978 shares in the company, valued at $87,306.06. This trade represents a 93.47 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 87,326 shares of company stock worth $8,673,948. Company insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.